SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Peak Pharmaceuticals, Inc. – ‘15-15D’ on 7/13/20

On:  Monday, 7/13/20, at 1:15pm ET   ·   Effective:  7/13/20   ·   Accession #:  1654954-20-7618   ·   File #:  333-156480

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/13/20  Peak Pharmaceuticals, Inc.        15-15D      7/13/20    1:22K                                    Blueprint/FA

Notice of Suspension of Duty to File Reports   —   Form 15   —   Sect. 12(g) or 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 15-15D      Peak Pharmaceuticals, Inc. Form 15                  HTML     13K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  peak_15  
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 15
 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Commission File Number
333-156480
 
PEAK PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 85260
Telephone: (480) 659-6404
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
 
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
Rule 12g-4(a)(1)
 
Rule 12g-4(a)(2)
 
Rule 12h-3(b)(1)(i)
 
Rule 12h-3(b)(1)(ii)
 
Rule 15d-6
 
 
Approximate number of holders of record as of the certification or notice date: 19
 
 
 
1
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: July 13, 2020
 
 
 
 
PEAK PHARMACEUTICALS, INC.
 
 
By:
 
 C: 
Name:
 
Neil Reithinger
Title:
 
Chief Executive Officer
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2

Dates Referenced Herein

This ‘15-15D’ Filing    Date    Other Filings
Filed on / Effective on:7/13/20None on these Dates
 List all Filings 
Top
Filing Submission 0001654954-20-007618   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 6:53:16.1am ET